Cancer Antigen 19.9 - Pancreatic Cancer Marker Test in New Friends Colony, Delhi

Pancreatic cancer is an aggressive tumor with the characteristic of dismal prognosis. The biomarkers which detect the tumor at early stage might be helpful in the terms of improving the prognosis. As of now only, serum CA 19-9 is the validated marker for the clinical use to check the presence of tumor. Serum CA 19-9 is used for the detection of the tumor. Pancreatic cancer is one of the widespread cancers leading to death of the peoples worldwide. The lethal nature and aggressiveness of the disease can be predicted by the fact that the death rate by pancreatic cancer is equivalent to the mortality rate. A revelation has been made from a population based survey that the survival chances in case of advanced pancreatic cancer is 5 years of 4-6 percent patients surfing from the disease. In 1979, Koprowski et al. used hybridoma technology and identified carbohydrate antigen 19-9, i.e., CA 19-9, which recognises sialo ganglioside with the use of monoclonal antibody, named, 1116-NS-19-9.